In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8 + T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.
INTRODUCTION
For metastatic or locally advanced solid tumors, neither current conventional treatments such as cytotoxic chemotherapy, radiotherapy (RT) nor the newer immunotherapies alone can effectively cure patients in many cases. Intensive chemotherapy reduces tumor cell burden and hardly eradicates all cancer cells in adult solid tumors. 1 Immunotherapy can improve T-cell responses in many patients, but it is only curative in a very small fraction of patients. 2, 3 Integration of conventional treatment and immunotherapy with the goal of curing advanced cancers is a major challenge to improve both treatments. In most cases, DNA damage and modulation of oncogenic signals have long been considered the major mechanisms responsible for the effects of conventional and targeted therapies. [4] [5] [6] As such, cell intrinsic signals involved in DNA repair, cell cycle checkpoints and signal transduction have been intensively accepted as dominant mechanisms determining the response to therapy. While manipulating cell intrinsic pathways has attracted much attention, several surprising studies implicated that chemotherapy and targeted treatment trigger immunity, contributing to the eradication of tumor cells. [7] [8] [9] The importance of the immune system in the responses to radiation, chemotherapy and targeted therapy has been observed in various syngeneic murine tumor models. Since then, many in-depth mechanistic studies on multiple immune pathways that regulate the response to therapy have been explored and identified. 10, 11 Here, we summarize the current state of mechanisms regarding treatment-induced adaptive immune responses. We place emphasis on recent data in radiation and targeted monoclonal antibody (mAb) therapies implicating the cytosolic DNA sensing and subsequent type I interferon (IFN) production as the critical innate immune steps in driving adaptive immunity.
THE INFLUENCE OF THE IMMUNE SYSTEM ON RADIATION EFFICACY
Local radiation modulates immunity for tumor control The rationale for RT stems from inducing lethal DNA damage to tumor cells or tumor-associated stroma. The most commonly administered RT regimens deliver small, fractionated doses of ionizing radiation over several weeks. Depending on the location of the tumor, its type, volume of normal tissue irradiated and tissue toxicity, a total dose of~60-80 Gy is divided into relatively small doses of 2-3 Gy per day. However, protracted fractionation may lead to tumor regrowth between doses. Very large (415 Gy) single radiation treatments or hypofractionated radiation treatments (10 Gy over five treatments) are administered to treat brain or spine metastasis. 12 Single dose or hypofractionated regimen is used with curative intent in the treatment of oligometastasis and localized lung cancer. 13 Importantly, the volume of surrounding normal tissue must be limited to avoid complications.
It has been increasingly observed that local RT can stimulate antitumor immune responses. Most studies have focused on the direct immunomodulating effects on the tumor cells via amplifying peptide repertoire and enhancing major histocompatibility complex class I expression on tumor cells. 14 Other reports have demonstrated that local radiation of tumors can modify the phenotype of tumor cells, rendering them more sensitive to vaccine-mediated T-cell killing. 15 Additionally, it has been proposed that local radiation changes the endothelium by reversing the non-adhesive phenotype of the tumor endothelium, contributing to increased infiltration of lymphocytes into tumor. 16 Consistently, it has been shown that the migration of tumor antigen (Ag)-specific effector cells to tumors increases after local radiation. 17 By inducing apoptosis and necrosis of tumor cells, RT can promote increased Ag presentation through both increased Ag availability and 'danger signal'-induced dendritic cell (DC) maturation. 18 A pioneering study showed that the immune system contributes to both RT and chemotherapy via the release of the high-mobility group box 1 (HMGB1) alarming protein from dying tumor cells and subsequently increase DC Ag processing and cross-presentation. 19 Subsequent studies identified immunogenic cell death post RT via (1) cell surface translocation of calreticulin (CRT) under ER stress; (2) release of extracellular HMGB1; (3) release of ATP during autophagy and (4) release of cellular RNA/DNA These danger signals are generally referred to as 'damage-associated molecular patterns' (DAMPs), which alarm the innate immune response to phagocyte tumor cell and activate the innate immune response post RT 22, 23 ( Figure 1) . Although many studies demonstrate that RT can trigger the innate immune activation, whether CD8 + T-cell immune response contributes to tumor reduction in a meaningful manner has remained unclear until recently.
Our group first reported that CD8 + T cells are essential for ablative radiation-induced tumor regression, which had changed the current understanding of how RT works. 2, 8 Further investigation of the mechanisms revealed that ablative RT markedly increases elimination of the primary tumor or distant metastasis (abscopal effect) in a CD8 + T-cell-dependent manner, which can be further amplified by combining with local immunotherapy. 8 Such immune activation effect of RT to reduce tumor burden can be sustained and elevated by subsequent immunotherapy. 8 Noticeably, while large amounts of neo-Ag may release post RT, the pre-existing immunosuppressive tumor microenvironment can restrict the antitumor immune response and the abscopal effect triggered by RT. Therefore, the understanding of the abscopal effect has the potential to change RT from a local and regional treatment modality to a modality that effectively treats distant metastasis and opens the door to combinations of RT and immunotherapy. To improve the efficacy of RT in conjunction with immunotherapy, the immunogenic characters of different RT schemes (e.g. stereotactic, fractionated) are considered to be necessary. 24 Some data have shown that when combined with immunotherapy, stereotactic RT showed stronger effect than a fractionated scheme. 25 On the contrary, some illustrated that fractionated RT can completely suppress tumor growth and lead to eradication in a mouse lymphoma model, while other regimens only slowed growth. 26 There are some possibilities that can explain the different immune response resulting from different radiation fraction schemes.
(1) Various rates of direct tumor cell killing led by different regimens. (2) A balance between immunostimulatory and immunoinhibitory effects of RT. 27 In all, finding equilibrium to maximize antitumor T-cell activation while minimizing immunoinhibitory effect is of great importance in optimizing the combination treatment effect.
Key for ideal integration between immunotherapy and RT Radiation-induced equilibrium or dormancy is a common feature in both clinical and preclinical radiated tumors. One view of late tumor recurrence is that the duration of progression-free/stable disease is determined by the very small number of surviving clones, which survive cytotoxic treatment and slowly adapt and create proper environment to repopulate. Therefore, the extent of massive cell death of tumor cell or stroma triggered by radiation is proposed to, predominantly, mediate the time to tumor relapse. 28 An alternative/complimentary explanation is the induction of tumor equilibrium, which is a state whereby tumor proliferation is balanced by cell death, and lack of angiogenesis mechanisms have been demonstrated to mediate tumor equilibrium, 29, 30 suggesting that there is a balance between cell growth and cell death because of insufficient angiogenesis, or intrinsic cellular factors. Our recent study revealed the immunologically based equilibrium after RT in which the active balance of tumor cell proliferation and T-cell-mediated killing is the major mechanism, resulting in RT-induced dormancy and equilibrium. 31 We observed an essential role for immune cells and their cytokines in maintaining RT-induced equilibrium. Depletion of T cells or neutralization of IFN-γ reversed such equilibrium, leading to tumor relapse. However, without any intervention, T cells are not functional enough to eradicate residual tumor cells over the course of achieving tumor equilibrium, and tumors eventually relapse. We demonstrated that PD-L1 blockade could disrupt the equilibrium by augmenting T-cell responses, leading to complete tumor regression. Considering such interplay between tumor cells and immune cells occurs in radiation-induced tumor equilibrium, immunotherapy should be involved in combinational treatments that tip over the balance for complete eradication.
Innate immune-sensing pathways serve as a bridge to an adaptive immune response in radiation therapy The mechanism of increased cross-priming and tumor-specific T-cell activation inside the tumor or draining lymph node has not been well illustrated. 32 Type I IFNs serve as a linker between innate responses and adaptive immunity. 33, 34 Interestingly, it has been shown that endogenous type I IFN production has a critical role not only in immune-editing of tumors but also in promoting DC maturation and stimulating the cross-priming of tumor-specific CD8 + T cells. 35, 36 Therefore, type I IFNs are indispensable components of host defense during tumor initiation and progression. Tumor Ags and danger signals released after local high-dose radiation may potentially trigger IFN pathway to increase cross-priming. Therefore, we demonstrated an effective antitumor adaptive immune response by revealing the potential role of type I IFNs in bridging the initial inflammation induced by radiation. 32 After RT, type I IFN inside the tumor is increased for rebridging the innate and adaptive immunity in the tumor microenvironment. More importantly, the diminished antitumor effect of RT in IFN-α/β receptor knockout hosts in comparison with wild-type mice demonstrated the potential physiological and clinical significance of our studies. A similar situation appears to be the case when RT is used in conjugation with immunotherapy strategies such as cancer vaccines. Consistent with our observations, type I IFN signaling is demonstrated to orchestrate the synergy of radiation and antigenic peptide vaccine. 37 Collectively, these findings lead to investigations of type I IFN agonists, which presumably contribute to eradicate the established radiation-resistant tumors.
When sufficient data points to type I IFNs after radiation, it is necessary to dissect the mechanism responsible for type I IFN production and develop therapeutics that targets this pathway. It is known that a diverse range of stimuli is able to trigger type I IFN production. For example, intracellular exogenous DNA has been demonstrated to be sensed by endoplasmic reticulum (ER)-associated protein STING (stimulator of IFN genes), which mediates type I IFN induction in a Toll-like receptor (TLR)-independent manner. 38, 39 Moreover, STING pathway stimulated by the aberrant cytoplasmic DNA leads to autoimmune diseases. 40 Following the recognition of cytosolic DNA, cGAS (cGAMP synthase) catalyzes the generation of cyclic GMP-AMP, which binds to and activates downstream STING signaling. 41 cGAS has been recently considered as an universal cytosol DNA sensor for STING activation in the setting of viral infection and lupus erythematosus. 42, 43 Notably, our study demonstrated that STING signaling, instead of MYD88 or TRIF signaling (two major TLR-associated pathways for IFN induction), is required for therapeutic effects of radiation, and mediated type I IFN response in DCs. Furthermore, STING signaling is required to elicit robust innate and adaptive immune response to radiation. Specifically, radiationmediated cell stress in tumor cells results in the release of danger signals that are recognized by DCs and in turn activate the cGAS-STING-IRF3-IFNβ axis 44, 45 ( Figure 1 ). These studies have not only pointed to the significance of nucleic acid-sensing pathways in effective antitumor immune responses and type I IFN induction after RT but also integrate current understanding of radiation-induced DNA damage into immune sensing. However, it is still unclear how tumor DNA can get into the cytosolic compartment of DC. Directly providing naturally produced cyclic GMP-AMP fails to activate DC, but additional local RT allows STING signaling, suggesting that radiation might change the local environment to provide additional condition, which allow tumor DNA to invade the cytosolic compartment of DC. An intriguing approach is to improve the physical and chemical properties of cyclic GMP-AMP that can actively enter the cytosolic compartment and signal the STING pathway. 46, 47 The local use of the modified molecules that can target to the cytosolic compartment can generate strong IFN and tumor regression. However, systemic delivery of such modified molecules might have higher toxicity and reduced tumor targeting. How to increase tumor targeting by systemic delivery remains to be determined.
Except for tumor-infiltrating macrophages and DCs, natural killer (NK) cells also contribute to antitumor effect by targeting malignant cells via direct cytolysis and secretion of potent immune mediators.
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NKG2D ligands, an activating receptor for NK cells, are demonstrated to be upregulated by RT, thus rendering irradiated tumor cells more susceptible to NK cell-mediated cytolysis. 49 In pancreatic and colon carcinoma, when tumor cells were exposed to radiation, heat-shock protein 70 will be induced, thereby targeting them for lysis by NK cells. 50 
THE INFLUENCE OF THE IMMUNE SYSTEM ON CHEMOTHERAPEUTIC EFFICACY
Chemotherapy-induced tumor cell death that elicits an antitumor immune response and immunological memory against tumorassociated Ags defines immunogenic cell death and has been well reviewed somewhere else. 23, [51] [52] [53] We only briefly summarize some key findings in this important field. It is reported that chemotherapeutic agents such as anthracyclines and oxaliplatin can induce immunogenic cell death. The dying tumor cells alert the immune system by expressing or releasing DAMPs via specific sensing pathways. 54, 55 There are several well-documented DAMPs such as increased expression of the endoplasmic reticulum protein CRT on the cell surface, 54,55 extracellular secretion of ATP 56, 57 and extracellular release of the non-histone chromatin protein HMGB1 19, 58 ( Figure 2) . Clinically, the expression of DAMPs, which are induced by RT or chemotherapy, have been shown to be related to patient' survival in various cancers. For oxaliplatin-treated colorectal cancer patients, tumor cell apoptosis induces CRT in tumor cells in early apoptosis phase and HMGB1 in late apoptosis phase. 59, 60 In patients with esophageal squamous cell carcinoma, the degree of HMGB1 positively correlated with patient survival. 61 Liu's group found that the soluble CRT level in serum samples from 58 lung cancer patients was significantly higher compared with that from 40 healthy individuals. 62 The predictive impact of DAMPs for RT and chemotherapy in cancer patients enlightened the concept of using immunogenic cell death as biomarkers/predictors of therapeutic responses and correlating them with immunological and/or clinical observations. TLR4 (Toll-like receptor 4) on Ag-presenting cells (APCs) can recognize tumor-derived DAMPs such as HMGB1 to stimulate DCs and enhance the antitumor T-cell response. In addition, nucleic acids released from chemotherapy-treated tumor cells can bind to TLRs or cytosolic nucleic acid sensors, which presumably contribute to antitumor immune responses by inducing type I IFNs. 63, 64 These findings, including seminal work from Zitvogel and Kroemer (see their review elsewhere), have demonstrated in detail that DAMPs are determined factors driving the innate immune recognition response and subsequent antitumor immunity. 52 Even though DAMPs are considered as a signal to alarm host immune system to get activated, whether it can always sufficiently mediate immunogenicity, leading to potent immune response, still remains a question. Zelenay and Reis e Sousa 65 summarized that immunogenicity can be composed by two basic properties: antigenicity and adjuvanticity. Antigenicity is defined as a given immunogen that can be recognized by lymphocytes and adjuvanticity denotes a substance's ability to promote the priming of lymphocytes. 65 According to this characterization, most of the DAMPs can be categorized as proinflammatory signals, while these molecules cannot be considered equivalent to the ability of promoting DC activation and adaptive immunity to associated foreign Ags (Figure 2) . However, there are some factors that compromise the interaction between chemotherapy/RT and host immune system. First, the expression and binding capacity of DAMPs will determine the therapeutic effects of conventional therapies. In breast cancer patients, Zitvogel and Kroemer's group 19 reported that a TLR4 polymorphism impairs HMGB1 binding to TLR4, which leads to early tumor relapse after anthracycline-based chemotherapy. 19 Second, some immunosuppressive cytokines induced by conventional therapies are shown to affect tumor microenvironment and host immune system. Transforming growth factor-β is known to be one of most potent immunosuppressor induced by RT by inhibiting APC maturation and effector CD8 + T-cell proliferation, promoting regulatory T cells or by generation of protumorigenic M2 macrophages. 66 How to properly use combinational therapy to avoid such effects has become an outstanding issue. The dose and schedule of each therapy could be important factors to consider.
THE INFLUENCE OF THE IMMUNE SYSTEM ON TARGETED mAb THERAPY
Adaptive immunity is essential for antitumor effects of targeted antibody therapy Antagonist antibodies of the oncogenic receptor tyrosine kinases prevent tumor cell growth by blocking cell survival signaling and triggering apoptosis pathways. Targeted antibodies including trastuzumab, cetuximab and rituximab are proved to prolong survival in patients with oncogene mutations or overexpression, respectively. 67, 68 The action of these mAbs principally was attributed to programmed cell death induction, complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC) and phagocytosis of mAb-opsonized target cells through FcγRs (receptors for the Fc portion of immunoglulin G) expressed on myeloid-derived cells, and NK cells (Figure 3) . In contrast to the wellknown direct killing mechanisms, the sustained effects of targeted antibody therapy on the host adaptive response have received little attention. Early clinical trials noticed that patients who previously received trastuzumab therapy exhibited a substantial increase of HER2 E75 peptide-specific CD8 + T-cell response, which was correlated with improved clinical outcomes. 69, 70 Similarly, two clinical observations imply that rituximab therapy provokes a 'vaccine' effect that might correlate with prolonged survival rate, but the causative effect cannot be established in such an observation. 71 While many studies have a correlation between immune activation and prolonged survival, whether or to what extent such adaptive immunity contributes to tumor regression has been difficult to establish by clinical observation. Furthermore, the mechanism by which the adaptive immune responses mediate antibody-mediated tumor control is still unknown. For mechanistic studies after different therapies, xenograft-transplanted tumor models were primarily used with a prolonged high dose of antibody.
Using a mouse mammary tumor isolated from HER2/neu transgenic mice in immunocompetent host, it was clearly demonstrated for the first time that the antitumor effect of anti-HER2/neu antibody mainly relies on the CD8 + T-cell response. 9 This study has been fully supported by others using different models. 9, 72 Anti-HER2/neu antibody therapy can induce tumor regression in Myd88-and IFN-dependent manner. Stress proteins induced by oncogenic receptor blockade might contribute to MyD88-dependent innate-sensing and subsequent T-cell activation for tumor regression. Therefore, antioncogenic receptor antibody can be synergized by antibodies that promote T-cell responses. 9, 72 Similarly, when reconstituting immune cells in Rag mice, the therapeutic effect of cetuximab in the presence of an adaptive immune system was more pronounced than immune-deficient mice. 73, 74 The consequent of DC-mediated cross-priming of Ags derived from mAb-covered cancer cells provoked a robust cytotoxic T-lymphocyte antitumor response. In the light of our data, we indicate that cytotoxic T-lymphocyte-dependent immunity may get involved in cetuximab-induced antitumor effects (Figure 3) .
In contrast, the effects of anti-CD20 on adaptive responses appear still obscure. The action of anti-CD20 antibody was principally attributed to CDC and ADCC. By using the receptor for the FcγR-deficient mice, the essential role of ADCC has been confirmed in the therapeutic function of anti-CD20 in the xenograft model. 75 For lymphoma depletion, FcγRI, FcγRIII and FcγRIV each contributed differently to the lymphoma depletion when treated with anti-CD20 mAb, suggesting that the type and activity of the FcγRs explain much of the efficacy of anti-CD20. 76, 77 Further study shows that anti-CD20 mAb becomes internalized via FcγRIIB on lymphoma cells, limiting the capacity of ADCC effect on elimination of tumor cells through innate immune effector cells. 78 In mantle cell lymphoma, patients with FcγRIIB-negative tumor biopsies showed a greater durable response when treated with a rituximab immune chemotherapy compared with 
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FcγRIIB-positive tumor biopsies, 79 emphasizing that ADCC has an important role in anti-CD20 therapy. Effective control of B-cell lymphoma by anti-CD20 in the xenograft models further suggests that direct killing or innate-mediated killing may be sufficient for the control of this type of tumor, while the role of adaptive immune system has not been defined. In the xenograft models, innate immune cells might be overly activated and their role in clearing tumor cells might be overestimated. 80 In contrast to the established direct cell death mechanisms, the long-term effects of targeted antibody therapy on the host adaptive response have received little attention. To study the effect of FDA-approved rituximab in the presence of immunocompetent host, human CD20 was transfected into EL4, a T-cell lymphoma model. Rituximab triggered an adaptive antitumor immune response in immunocompetent mice and provided long-lasting antitumor protection. 52 By using the same model, another group showed that anti-CD20 treatment generated protective memory T-cell responses through different FcγRs, but the role of T cells in the primary treatment was not demonstrated. 81 As the anti-CD20 therapy is more potent in mediating B-cell depletion and represents a breakthrough in B-cell lymphoma treatment, the function of adaptive immune response, especially CD8 + T cells, in the therapeutic activity of anti-CD20 mAb in B-cell malignancies, nonetheless, still requires further elucidation.
Unlike other targeted mAbs, anti-CD47 mAb binds to and blocks a 'don't eat-me' molecule CD47. 82 As CD47 is broadly expressed on multiple cancer types, it represents a novel tractable and potentially applicable target for therapeutic blockade in patients. 80 Human CD47-blocking mAbs have demonstrated an antitumor effect in various preclinical tumor models, and the therapeutic efficacy of antihuman CD47 is largely considered to enhance antitumor phagocytosis by macrophages. 82, 83 However, these studies used human tumor xenografts in T-cell-deficient mice, and innate cells might be overly activated. Therefore, they failed to assess the role of adaptive immunity in the virtue of CD47 blockade. Using syngeneic mouse models of cancer in immune-competent host, rather than transplanted xenografts in T-cell-deficient mice, it was first demonstrated that most of the therapeutic effect mediated by the anti-CD47 mAb depends on CD8 + cytotoxic T-cell response, as the antitumor effect of the CD47 antibody was abrogated in T-cell-deficient mice or CD8 + cell-depleted, tumor-bearing hosts. 84 Taken together with the observation of anti-HER2 and anti-EGFR, these findings reinstate that targeted mAb therapy can exert its therapeutic effects through the induction of an adaptive cellular immune response, aside from well-characterized tumor intrinsic mechanisms.
INNATE IMMUNE-SENSING PATHWAYS SERVE AS A BRIDGE TO AN ADAPTIVE IMMUNE RESPONSE IN TARGETED THERAPY
DCs are essential for generating tumor-specific T-cell responses in response to Ab-based targeted therapy as it expresses an array of FcRs that are responsible for cross-presentation of Ag-antibody complexes for cross-priming. 85 Ag processing by uptaking apoptotic tumor cells is also associated with enhanced cross-priming by DCs. 86 Uptaking tumor Ags by DCs could be facilitated by targeted mAb, which helps to elicit the activation and proliferation of CD4 + and CD8 + tumor-specific T cells. Insight into this process has stemmed from the finding that cell death triggered by targeted therapy releases large amounts of tumor-derived DAMPs, which can increase Ag presentation by DCs for improving cytotoxic T-lymphocyte priming. 9, 72 The major DAMP driving host antitumor immune response varies in different therapies. For example, the antitumor effect of anti-HER2 was proved to depend on DC through a HMGB1-MyD88-dependent way in the immunecompetent HER2-positive breast cancer models.
9,72 Neutralization of HMGB1 markedly abolished the efficacy of anti-HER2 therapy. In this context, HMGB1 as endogenous danger signal is critical for antibody-mediated tumor control. These observations were confirmed and extended by another study demonstrating that anti-HER2 therapy depends on HMGB1-TLR axis through MyD88, thereby causing the release of type I IFNs to activate the adaptive immune response. 50 Using neutralizing antibodies, it was demonstrated that IFNAR1, which is the receptor of type I IFNs, is required for anti-HER2 treatments. 9, 72 Consistently, as the upstream for T-cell priming against tumor-associated Ags, type I IFNs was also required in anti-EGFR mAb therapy. It was shown that cetuximab can promote opsonization and phagocytosis of tumor cells by human DCs, which were engaged in Ag cross-presentation and CD8 + T-cell activation via both the FcR and MyD88 pathways. 73 In addition, as the critical cytokine for cross-priming, type I IFN levels were demonstrated that correlated with the sensitivity of tumors to anti-EGFR in mouse tumor models, which raised the possibility that lower levels of type I IFNs may limit immune responses and additional type I IFNs may control Ab-resistant tumor growth. 87 In accordance with this, the potency of anti-EGFR mAb with IFNβ was higher compared with the first generation of Ab in eliminating Ab-resistant tumors. Therefore, induction of type I IFN production is a citical output from whatever innate immune-sensing pathways recognize the presence of cancer in vivo. Anti-CD47 mAb also bridges DC activation and cytotoxic T-lymphocyte priming through type I IFN. The ability of Ag cross-presentation by DCs has been enhanced after anti-CD47 therapy. 84 As a consequence, priming or enhancing CD8 + effector T cells against tumor-specific Ags can be achieved by the CD47 blockade mAb. Interestingly, unlike anti-HER2 and anti-EGFR, the major innate-sensing pathway driving type I IFN production and adaptive immune response for tumor control is the cytosolic DNA-sensing signaling STING, which is expressed by DCs. However, MyD88 signaling that is used by Toll-like receptors was not required. How DNA from mAb-treated tumor cells is delivered and why DNA sensing through STING is essential in this model remain to be determined. Relapse eventually occurs even in the face of even integrated chemotherapy plus immunotherapy. This failure may result from immunotherapy assistance or chemo-induced immune downregulation. The integration of anticancer treatment with immunotherapy can not only decrease the size of the primary tumor but also changer tumor microenvironment. Thus, it is important to carefully monitor the frequency of combined treatments, the concentration of agents and the sequence of administration. Our study demonstrates that when anti-CD47 antibody is administered after chemotherapy, the antitumor effect will be enhanced. 84 Therefore, when and which chemotherapy can elevate the efficacy of antibody in tumor eradiation in the settings of neoadjuvant, adjuvant and metastasis settings needed further consideration.
CONCLUSIONS
In this review, we postulate that in addition to immune checkpoint inhibitors, enhancing innate immune sensing for type I IFN induction is an essential tool for tumor management via conventional therapy and targeted mAb therapy. Type I IFN signaling reinforces DC activity and then promotes CD8 + T-cell cross-priming, leading to tumor control. Multiple DNA/RNA-sensing pathways contribute to the induction of type I IFN, and the corresponding agonists have displayed the potential ability to improve the overall response to combinational therapy. So far, the detailed mechanisms of the combinations are still not well defined. To translate these discoveries into practice, it will be necessary to further determine the toxicity and synergy of conventional and targeted therapy with nucleic acidsensing agonists in the clinic, as well as to develop carriers for effective delivery of agonists to tumor sites to improve overall response.
